喘息予防薬の世界市場:ICS/LABA配合剤、免疫抑制薬、ロイコトリエン拮抗薬、マスト細胞安定化剤、吸入ステロイド薬...市場調査レポートについてご紹介

【英文タイトル】Global Preventive Asthma Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Product profiles
Accolate
Pulmicort
Symbicort
Xolair
Advair
Anoro Ellipta
Arnuity Ellipta
Breo Ellipta
Flovent
Serevent
Ventolin
Asmanex
Foradil
Dulera
Singulair

PART 06: Disease overview
Understanding the disease
Symptoms
Pathophysiology
Epidemiology
Diagnosis
Management

PART 07: Pipeline Portfolio

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by class of drug

PART 10: ICS/LABA combination
Global ICS/LABA combination market

PART 11: Immuno-suppressants
Global immunosuppressants market

PART 12: Leukotriene antagonists
Global leukotriene antagonists market

PART 13: Mast cell stabilizers
Global mast cell stabilizers market

PART 14: Inhaled corticosteroids
Global inhaled corticosteroids market

PART 15: Geographical segmentation
Global preventive asthma drugs market by geography 2014-2019
Preventive asthma drugs market in Americas
Preventive asthma drugs market in EMEA
Preventive asthma drugs market in APAC

PART 16: Market drivers

PART 17: Impact of drivers

PART 18: Market challenges

PART 19: Impact of drivers and challenges

PART 20: Market trends

PART 21: Vendor landscape
Competitive scenario
Other and future prominent vendors

PART 22: Key vendor analysis
AstraZeneca
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Novartis

PART 23: Appendix
List of abbreviations

PART 24: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Major diagnostic procedures for asthma
Exhibit 03: Major drugs under development for asthma
Exhibit 04: Global preventive asthma drugs market ($ millions)
Exhibit 05: Five forces analysis
Exhibit 06: Segmentation of global preventive asthma drugs market by class of drug
Exhibit 07: Segmentation of global preventive asthma drugs market by class of drug 2014
Exhibit 08: Global preventive asthma drugs market: Market share by class of drug 2014-2019 ($ millions)
Exhibit 09: Global ICS/LABA combination market 2014-2019 ($ millions)
Exhibit 10: Global immunosuppressants market 2014-2019 ($ millions)
Exhibit 11: Global leukotriene antagonists market 2014-2019 ($ millions)
Exhibit 12: Global mast cell stabilizers market 2014-2019 ($ millions)
Exhibit 13: Global corticosteroids market 2014-2019 ($ millions)
Exhibit 14: Global preventive asthma drugs market by geography 2014
Exhibit 15: Global preventive asthma drugs market: Market share by region 2014-2019 ($ millions)
Exhibit 16: Preventive asthma drugs market in Americas 2014-2019 ($ millions)
Exhibit 17: Preventive asthma drugs market in EMEA 2014-2019 ($ millions)
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Sales of Pulmicort in US 2011-2014 ($ millions)
Exhibit 21: Global sales of Pulmicort 2011-2014 ($ millions)
Exhibit 22: AstraZeneca: Key takeaways
Exhibit 23: Sales of Xolair in the US 2011-2014 ($ millions)
Exhibit 24: F. Hoffmann-La Roche: Key takeaways
Exhibit 25: Global sales of Ventolin 2011-2014 ($ millions)
Exhibit 26: Global sales of Flovent 2011-2014 ($ millions)
Exhibit 27: Global sales of Advair 2011-2014 ($ millions)
Exhibit 28: Global sales of Serevent 2011-2014 ($ millions)
Exhibit 29: GlaxoSmithKline: Key takeaways
Exhibit 30: Global sales of Asmanex 2011-2013 ($ millions)
Exhibit 31: Global sales of Dulera 2011-2013 ($ millions)
Exhibit 32: Global sales of Singulair 2011-2013 ($ millions)
Exhibit 33: Merck: Key takeaways
Exhibit 34: Sales of Xolair (ex-US) 2011-2014 ($ millions)
Exhibit 35: Key takeaways: Novartis
Exhibit 36: AstraZeneca: Business segmentation by revenue 2014
Exhibit 37: AstraZeneca: Business segmentation by revenue 2013 and 2014
Exhibit 38: AstraZeneca: Geographical segmentation by revenue 2014


【レポート販売概要】

■ タイトル:喘息予防薬の世界市場:ICS/LABA配合剤、免疫抑制薬、ロイコトリエン拮抗薬、マスト細胞安定化剤、吸入ステロイド薬
■ 英文:Global Preventive Asthma Drugs Market 2015-2019
■ 発行日:2015年10月7日
■ 調査会社:Technavio
■ 商品コード:IRTNTR7196
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。